Amgen lung cancer combination cuts death risk 58%

Amgen’s Imdelltra combined with AstraZeneca’s Imfinzi cut the risk of death by 58% in a lung-cancer trial. Median survival reached 21.1 months versus 12.7 months with Imfinzi alone.